USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Caldera Pharmaceuticals, Inc.
Address:
278 DP Road Suite D
LOS ALAMOS, NM
Phone:
(505) 412-2345
URL:
N/A
EIN:
200982060
DUNS:
147452275
Number of Employees:
12
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,143,994.00 9
SBIR Phase II $4,111,289.00 3
STTR Phase I $300,000.00 3

Award List:

High-throughput Direct Structural Screening for Drug Lead Compounds

Award Year / Program / Phase:
2006 / STTR / Phase I
Award Amount:
$100,000.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Research Institution:
LOS ALAMOS NATIONAL LABORATORY
RI Contact:
Christy Ruggiero
Abstract:
U.S. Government personnel deployed in tropical and neotropical regions continue to be at risk for developing malaria. Drug resistant malaria parasites are becoming more common in these areas, increasing the risk of American personnel developing a serious, life-threatening disease. Cross resistance… More

Chemical and Biological Agent Deny: Selective Phosphate Ester Hydrolysis

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$99,985.00
Agency / Branch:
DOD / DTRA
Principal Investigator:
Michael Harris, Senior Biologist
Abstract:
This proposed work will generate a targeted phosphate ester hydrolysis catalyst for agent denial. This catalyst will be targeted by conjugation to single stranded DNA. Characteristics of the catalyst will be determined, including ruggedness, targeting selectivity, and potential methods for… More

Adherence Assessment for Supplements

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$245,093.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The use of dietary supplements has become increasingly popular in the US, and these supplements are not subject to stringent pre-marketing testing or post-marketing surveillance. More than a third of American adults report using some form of CAM, with total… More

Generation of Peptide-Based Ligands for Chemical and Biological Agent Identification

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$100,000.00
Agency / Branch:
DOD / USAF
Principal Investigator:
Abstract:
Caldera will use its R&D 100 award-winning Reagentless Pharmacoproteomic Measurement (RPM) technology to develop chemical/biological (C/B) agent taggants for incorporation into a portable read-out device. RPM technology was developed at Los Alamos National Laboratory and licensed to Caldera. We… More

Novel Micro-X-ray Translucent Flow Cell Technology for Proteomics, a Broadly Appl

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$400,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Caldera Pharmaceutical's aim is to develop a broadly applicable, quantitative research tool which addresses core technical challenges in the field of proteomics, including protein-drug interactions, protein-protein inte ractions, and post-translational… More

Biomarkers of Response to Environmental Stressors: Measurement of Environmental E

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$299,999.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant) Caldera Pharmaceutical's will use their unique, RandD100-award-winning Reagentless Pharmacoproteomic Measurement (RPM) high-throughput technology to identify biomarkers of response to environmental stressors (BRES ). Caldera developed RPM in collaboration… More

Adherence Assessment for Supplements

Award Year / Program / Phase:
2007 / SBIR / Phase II
Award Amount:
$375,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Caldera Pharmaceuticals uses protein fractionation techniques and XRpro technology to determine protein CAM/metabolite binding as a means to determine adherence to CAM regimens in NCCAM clinical trials. Caldera will us e their high-throughput proteomics… More

Biomolecular Taggants for Covert Tracking and Watermarking

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$100,000.00
Agency / Branch:
DOD / USAF
Principal Investigator:
Abstract:
Caldera will use its R&D 100 award-winning XRpro technologyto develop functional biomolecular taggants for Chemical/Biological/Radiological/Nuclear/Explosive (CBRNE) targets. These taggants will possess functionality which will allow networks of interpersonal connections and travel to be… More

Iron Man: Novel Technologies for Autonomous Defense

Award Year / Program / Phase:
2009 / STTR / Phase I
Award Amount:
$100,000.00
Agency / Branch:
DOD / DARPA
Principal Investigator:
Research Institution:
Harvard Medical School
RI Contact:
Nicole Touchet
Abstract:
Caldera Pharmaceuticals proposes to develop a highly metal-selective system to maintain iron concentrations in the body at optimal levels to prevent infections. The system will control iron without the loss of other essential micronutrients; loss of micronutrients is the cause of toxicity in most… More

XRpro Discovery of Decorporation Agents

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Caldera Pharmaceuticals will use award-winning XRpro, a high throughput, label-free technology for producing nano-engineered radionuclide decorporation agents that are highly specific for their target radionuclide over similar elements. This proposal displays… More

Biomolecular Taggants for Covert Tracking and Watermarking

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$736,289.00
Agency / Branch:
DOD / USAF
Principal Investigator:
Abstract:
Functional taggants are paints or inks that change their optical properties in response to specified environmental conditions, such as the presence of a chemical related to illicit weapon activities. In this project, we will develop taggant systems for two non-conventional weapon signatures.… More

Probes for Transient Kinase Complexes

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$98,917.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Most cellular processes are regulated by reversible protein phosphorylation, which is controlled by protein kinases and phosphatases. Caldera Pharmaceuticals and MedChem Partners propose to develop new probes for charac terizing transient protein complexes. MAPK… More

XRpro Technology for the Detection and Evaluation of Carcinogens

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$200,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Caldera Pharmaceuticals will develop quantitative biomarker assays for a set of carcinogens. In Phase I, Caldera will demonstrate the feasibility of using its novel XRpro(R) technology to extract, concentrate, quantify, and characterize carcinogens from… More

Selective Decorporation Agents for NIAID

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$3,000,000.00
Agency:
HHS
Principal Investigator:
Benjamin P. Warner – 505-412-2345
Abstract:
DESCRIPTION (provided by applicant): This Phase II project continues the successful Phase I discovery of novel decorporation agents that are selective for radioactive strontium (Sr). This project consists of the necessary steps for submission of an Emergency Use Authorization (EUA) or… More